Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma

被引：22

作者：

Figlin, Robert A. ^{[1
,2
,3
,4
]}

机构：

[1] Cedars Sinai Med Ctr, Hematol Oncol, Los Angeles, CA USA

[2] Cedars Sinai Med Ctr, Med & Biomed Sci, Los Angeles, CA USA

[3] Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA USA

[4] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2015年 / 15卷 / 08期

关键词：

AGS-003; autologous dendritic cell vaccine; immunotherapy; mTOR; overall survival; renal cell carcinoma; sunitinib; targeted therapy; VEGF; INTERFERON-ALPHA; DENDRITIC CELLS; DOUBLE-BLIND; PHASE-I; IMMUNE-RESPONSE; CANCER; TRIAL; INTERLEUKIN-2; TEMSIROLIMUS; BEVACIZUMAB;

D O I：

10.1517/14712598.2015.1063610

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction: AGS-003 is a novel autologous dendritic cell vaccine currently in Phase III clinical development in combination with sunitinib for patients with intermediate- and poor-risk clear cell metastatic renal cell carcinoma (ccmRCC). Areas covered: In addition to research published within the past 15 years demonstrating the efficacy of novel targeted therapies, early-phase clinical trial results recently published for AGS-003 in combination with sunitinib are discussed, as well as the ongoing Phase Ill clinical trial Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma. Expert opinion: AGS-003 in combination with sunitinib is a rational step forward for the clinical management of patients with ccmRCC. If the Phase III Advanced Renal Cell Carcinoma trial is positive, this treatment modality will provide a significant survival benefit with minimal toxicity and could change the standard of care for ccmRCC.

引用

页码：1241 / 1248

页数：8

共 63 条

[11] Controllers of the immune system and a new promise for immunotherapy [J].